Recursion Pharmaceuticals Inc Class A RXRX
News
Recursion Announces Pricing of $200 Million Underwritten Offering of Class A Common Stock
Recursion Announces $200 Million Oversubscribed Follow-On Offering, Clinical Data Updates, and Partnership Milestone
Recursion Reports Second Quarter Financial Results; Genentech Options First Neuroscience Target into Early Discovery Program
Recursion to Participate in Upcoming Investor Conferences
Recursion Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules
Recursion to Report Second Quarter 2026 Business Updates and Financial Results on August 5th
